Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients
- PMID: 3602021
Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients
Abstract
Twenty-one insulin-dependent and 30 non-insulin-dependent diabetic patients were treated over 48 months with pentoxifylline ('Trental' 400) 1200 mg/day orally. All patients had haemorheological alterations and vascular complications. A marked improvement in erythrocyte deformability and a reduction in plasma fibrinogen levels was already evident after 6 months of therapy; these improvements were maintained throughout the 48 months of the study and were independent of short-term and long-term glycometabolic changes. The normalization of blood rheology pattern was associated with a significant decrease in total urinary protein excretion rate and in urinary albumin excretion rate. An improvement in both microvascular, i.e., retinopathy and nephropathy, and macrovascular, i.e. ischaemic heart disease and peripheral occlusive arterial disease, complications was demonstrated after the long-term trial with pentoxifylline. No side-effects occurred during the observation period. These data suggest that pentoxifylline may have an important role in both the treatment of diabetic haemorheological changes and renal disorders and in the prevention of accompanying degenerative vascular complications.
Similar articles
-
Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline.Pharmatherapeutica. 1985;4(6):341-50. Pharmatherapeutica. 1985. PMID: 4080752
-
[Pentoxifylline and arterial hypertension in diabetes mellitus: long-term results in randomized groups].Ric Clin Lab. 1985;15 Suppl 1:515-26. Ric Clin Lab. 1985. PMID: 4035232 Clinical Trial. Italian.
-
[Erythrocyte filterability and treatment with pentoxifylline].Ric Clin Lab. 1983;13 Suppl 3:455-8. Ric Clin Lab. 1983. PMID: 6673029 Clinical Trial. Italian.
-
Losartan in diabetic nephropathy.Expert Rev Cardiovasc Ther. 2004 Jul;2(4):473-83. doi: 10.1586/14779072.2.4.473. Expert Rev Cardiovasc Ther. 2004. PMID: 15225108 Review.
-
[The biology of fibrinogen. The role of pentoxifylline].J Mal Vasc. 1989;14 Suppl A:25-8. J Mal Vasc. 1989. PMID: 2654312 Review. French.
Cited by
-
Hydroxyurea stimulates the release of ATP from rabbit erythrocytes through an increase in calcium and nitric oxide production.Eur J Pharmacol. 2010 Oct 25;645(1-3):32-8. doi: 10.1016/j.ejphar.2010.07.012. Epub 2010 Jul 23. Eur J Pharmacol. 2010. PMID: 20655902 Free PMC article.
-
Pentoxifylline for diabetic retinopathy.Cochrane Database Syst Rev. 2008 Apr 16;2008(2):CD006693. doi: 10.1002/14651858.CD006693.pub2. Cochrane Database Syst Rev. 2008. PMID: 18425965 Free PMC article.
-
Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy.Acta Diabetol Lat. 1987 Jul-Sep;24(3):229-39. doi: 10.1007/BF02732042. Acta Diabetol Lat. 1987. PMID: 3687315 Clinical Trial.
-
Treatment of homozygous sickle cell disease with pentoxifylline.J Natl Med Assoc. 1999 Aug;91(8):466-70. J Natl Med Assoc. 1999. PMID: 12656436 Free PMC article.
-
Essential fatty acid treatment of rats with experimental diabetes: comment.Diabetologia. 1994 Mar;37(3):331. doi: 10.1007/BF00398063. Diabetologia. 1994. PMID: 8174850 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical